Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Athina Rigalou"'
Autor:
Serika D Naicker, Claire L Feerick, Kevin Lynch, Dawn Swan, Cian McEllistrim, Robert Henderson, Niamh A Leonard, Oliver Treacy, Alessandro Natoni, Athina Rigalou, Joana Cabral, Christopher Chiu, Kate Sasser, Thomas Ritter, Michael O’Dwyer, Aideen E Ryan
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Multiple Myeloma (MM) is a malignant disorder of plasma cells which, despite significant advances in treatment, remains incurable. Daratumumab, the first CD38 directed monoclonal antibody, has shown promising activity alone and in combination with ot
Externí odkaz:
https://doaj.org/article/c2aa7a8efc5244f4b92d73ee74984420
Autor:
Kevin Lynch, Serika D. Naicker, Joana Cabral, Thomas Ritter, Oliver Treacy, Kate Sasser, Niamh A Leonard, Christopher Chiu, Dawn Swan, Alessandro Natoni, Cian McEllistrim, Athina Rigalou, Claire L. Feerick, Robert Henderson, Michael O'Dwyer, Aideen E. Ryan
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
Multiple Myeloma (MM) is a malignant disorder of plasma cells which, despite significant advances in treatment, remains incurable. Daratumumab, the first CD38 directed monoclonal antibody, has shown promising activity alone and in combination with ot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::814613750f1cd53cb7e1e59642e64cd0
https://doi.org/10.1080/2162402x.2020.1859263
https://doi.org/10.1080/2162402x.2020.1859263
Autor:
Thomas Ritter, Paul Lohan, Laurence J. Egan, Aideen E. Ryan, Kevin Lynch, Athina Rigalou, Grace O’Malley, Serika D. Naicker
Publikováno v:
Cancer Research. 77:2693-2693
The colon tumour microenvironment (TME) comprises many cell types including endothelial cells, stromal cells and immune cells. Recent evidence suggests that high tumour stromal cell density correlates with a poor prognosis for colon cancer patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8fb344eb772dcf59310efb56d21e46a9
https://doi.org/10.1158/1538-7445.am2017-2693
https://doi.org/10.1158/1538-7445.am2017-2693
Autor:
Alessandro Natoni, Kate Sasser, Michael O'Dwyer, Aideen E. Ryan, Athina Rigalou, Christopher Chiu
Publikováno v:
Blood. 128:2101-2101
Introduction Daratumumab (Dara) is the first CD38-directed monoclonal antibody (moAb) approved anywhere in the world as well as the first moAb approved for the treatment of Multiple Myeloma (MM). While currently approved as monotherapy, recent result
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72f0c69ebe9c558d87f8dc9c86d67256
https://doi.org/10.1182/blood.v128.22.2101.2101
https://doi.org/10.1182/blood.v128.22.2101.2101